We use cookies and other technologies on this website to enhance your user experience.
By clicking any link on this page you are giving your consent to our Privacy Policy and Cookies Policy.
Icona S.A. Clinical Guidelines and EML

2.0.0 by Jembi Health Systems


Apr 7, 2021

Informazioni su S.A. Clinical Guidelines and EML

Linee guida cliniche approvate da NDoH con elenco di farmaci essenziali

This app includes the Standard Treatment Guidelines and Essential Medicines List for South Africa.

The guidelines are published by the Department of Health. Essential Medicines meet the priority healthcare needs of the population. The Standard Treatment Guidelines (STGs) guide their rational use.

By using a mobile application we seek improved access and support implementation of the STGs and EML at all levels of care.

This app facilitates:

• Point-of-care access to the latest STGs and EML.

• Use of clinical calculation tools to assist with decision-making.

The application contains the STGs and EML for:

• Primary Healthcare

• Hospital Level: Adults

• Hospital Level: Paediatrics

• Tertiary and Quaternary Level

Full details of formulation and revision of these guides is available in the About section of this app.

Any comments or queries on the STGs and EML can be directed to the EDP at [email protected]

Novità nell'ultima versione 2.0.0

Last updated on Apr 7, 2021

Updated the source of the content to production servers.

Traduzione in caricamento...

Informazioni APP aggiuntive

Ultima versione

Richiedi aggiornamento S.A. Clinical Guidelines and EML 2.0.0

Caricata da

Anang M

È necessario Android

Android 5.1+

Mostra Altro

S.A. Clinical Guidelines and EML Screenshot

Lingua
Iscriviti ad APKPure
Sii il primo ad accedere alla versione anticipata, alle notizie e alle guide dei migliori giochi e app Android.
No grazie
Iscrizione
Abbonato con successo!
Ora sei iscritto ad APKPure.
Iscriviti ad APKPure
Sii il primo ad accedere alla versione anticipata, alle notizie e alle guide dei migliori giochi e app Android.
No grazie
Iscrizione
Successo!
Ora sei iscritto alla nostra newsletter.